The Supplant Company

Supplant is a very small company — reported at roughly a dozen employees — with no verified funding round since its 2021 Series A, which makes it one of the thinnest-capitalized names in this batch trying to solve one of the hardest problems in food: scaling an enzymatic conversion of heterogeneous agricultural waste into a food-grade sweetener at a cost that competes with sugar. Sugar is astonishingly cheap and functionally perfect, and the graveyard of sugar-reduction startups is deep; "sugars from fiber" must clear cost parity while navigating variable, contaminated feedstock streams that resist industrial standardization. The business model is unproven at scale — it needs either its own branded products or B2B ingredient supply, and neither shows disclosed traction; celebrity-chef chocolate is a marketing proof point, not a revenue base. Regulatory novelty adds friction in every geography. With minimal headcount and stale funding in a food-tech capital drought, Supplant risks being a technically elegant idea that never reaches the volumes and price point required to matter, out-resourced by incumbent sweetener giants and better-funded sugar-reduction rivals if the category does inflect. Public information on its current commercial and financial state is sparse, which is itself a warning sign for a company five-plus years past founding.